The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In the first episode of The Deep End Podcast, we meet Jon Nelson, who shares why he volunteered to get brain implants for his relentless depression.

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

Researchers at CU Anschutz are studying the effect of psychedelic mushrooms on patients with treatment-resistant depression.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

A trial for psilocybin therapy to treat depression is being opened to Vancouver Island applicants. Psilocybin is a ...

A trial for psilocybin therapy to treat depression is being opened to applicants in the Nanaimo area. Psilocybin is a ...

GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...